COMPARISON OF THE VALUE OF INFLAMMATION MARKERS AND HEART REMODELING PARAMETERS IN PATIENTS WITH DISTINCT TYPES OF ATRIAL FIBRILLATION

Results. By the cluster-analysis method we found that except the remodeling parameters in paroxysmal and persistent AF important role do play the levels of such markers as C-reactive protein (C-r.p.) and inlerleukine-6 (IL-6). In patients with permanent form of atrial fibrillation inflammation markers levels do not play key role. Conclusion. C-r.p. and inflammatory cytokines play some role in pathogenesis of AF, especially in its paroxysmal and persisting types. And as C-r.p., being an acute phase protein, cannot be the specific marker of inflammation in AF, but the increase of C-r.p. might be the predictor of IL-6 level increase, especially in paroxysms and returns of Af.

1. Adamyan KG, Grigoryan SV, Hazarapetyan LG. The role of latent inflammation in AF pathogenesis. Vestnik Arimmologii 2008; 54: 34-41. Russian (Адамян К. Г., Григорян С. В., Азарапетян Л. Г. Роль латентного воспаления в патогенезе фибрилляции предсердий. Вестник аритмологии 2008; 54: 34-41).

2. Hazarapetyan LG, Budagyan LG, Agababova MA, et al. Prognostic value of of some markers of inflammation in different clinical forms of atrial fibrillation. Scientific works of YII Cardiology Congress of Armenia, 2009;104-7. Russian (Азарапетян Л. Г., Будагян Л. Г., Агабабова М. А. и др. Прогностическая значи¬мость некоторых маркеров воспаления при различных клинических формах мерцательнорй аритмии. Научные труды YII Конгресса кардиологов Армении 2009; 104-7).

3. Kuschakovski MS Cardiac arrhythmia. Guide for Physicians, St. Petersburg.: IKF "Foliant" 2004; 672 р. Russian (Кушаковский М. С. Аритмии сердца. Руководство для врачей. СПб.: ИКФ "Фолиант" 2004; 672 с).

4. Cheruku KK, Ghani A, Ahmad F, et al. Efficacy of nonsteroid anti-inflammatory medications for prevention of atrial fibrillation following coronary bypass graft surgery. Prev Cardiol 2004; 7; 13-8.

5. Ridker PM. Targeting inflammatory pathways for the treatment of cardiovascular disease. Eur Heart J 2014; 35(9): 540-3.

6. Guidelines for the management of atrial fibrillation. The Task Forse for Management of Atrial Fibrillation of the ESC. Eur Heart J 2010; 31: 2369-429.

7. Nasonov EL, Panjukova EV, Alexandrova EN. C-reactive protein as a inflammation marker on atherosclerosis (new data). Kardiologia 2002; 7: 53-62. Russian (Насонов Е.Л., Панюкова Е.В., Александрова Е. Н. С-реактивный белок — маркер воспаления при атеросклерозе (новые данные) Кардиология 2002; 7: 53-62).

8. Grigoryan SV, Adamyan KG, Hazarapetyan LG, et al. Atrial fibrillation and anti- inflammatory medication with Nimesulde. ESC Congress Stockholm-Sweden, 27 August — 1 September 2010; 31.

9. Boss ChJ, Anderson RA, Lip GYH. Is atrial fibrillation an inflammatory disorders? Eur Heart J 2006; 27: 136-49.

10. Hernandez A. C-reactive protein and atrial fibrillation. An old marker looking for new target. Rev Esp Cardiol 2006; 59: 94-8.

11. Dernellis J, Panaretou M. Effect of C-reactive protein reduction on paroxysmal atrial fibrillation. Am Heart J 2005; 2005,150, 1064.e7-1064.e12.

12. Engelmann MDM, Svedsen JH. Inflammation in the genesis of atrial fibrillation. Eur Heart J 2005; 20(26): 2083-92.

13. Kallergis EM, Jais P, Khalil SI, et al. The role of the post-cardioversion tive course of hs-CRP levels in clarifying the relationship between inflammation and persistence of atrial fibrillation. Heart rhythm disorders and pacemakers 2007; 2: 443-6.

14. Wazni O, Martin DO, Marrouche NF, et al. C-reacrive protein concentration and recurrence of atrial fibrillation after electrical cardioversion. Heart J 2005; 91: 1303-5.